#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small cell lung cancer limited stage Squamous cell carcinoma of the cervix Proteus syndrome Homocystinuria Urea cycle disorder Myotonic dystrophy Hepatic angiosarcoma Liver abscess Herpes simplex Autoimmune disorder Ehlers-Danlos syndrome Acute myeloid leukaemia recurrent Epilepsy Renal cell carcinoma Prophylaxis against transplant rejection More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia recurrent – Basic Information Gaucher’s disease type I – Basic Information Mantle cell lymphoma stage IV – Trials in Disease Ornithine transcarbamoylase deficiency Factor IX deficiency – Life with Disease Angelman’s syndrome Chronic granulomatous disease – Diagnostics Brain stem glioma – Life with Disease Waldenstrom’s macroglobulinaemia – Diagnostics Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Motixafortide [14C]ZIPALERTINIB LY3372993 GSKVX000000040033 Escitalopram Oxalate Basimglurant Gen1053 Charcoal, Activated Magnesium Sulfate Disodium Folinate DNL593 Alendronate Sodium Monohydrate Tasimelteon Sodium Iodide (131I) Specific Nucleic Acid Sna-Xfsb Erythromycin Lactobionate 10-1074-Ls Bortezomib Ltx-315 Human Coagulation Factor Ii More therapies…

    Learn about Your Condition

    Bone sarcoma Ocular lymphoma Palmoplantar pustulosis Vaginal haemorrhage Bacterial prostatitis Skin disorder Hyperkalaemia Pathogen resistance Alcohol use disorder Erythema multiforme Corneal graft failure Desmoid tumour Aplastic anaemia Staphylococcal infection Pyoderma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Adenocarcinoma
    • Non-small cell lung cancer
    • Ovarian cancer
    Investigated Drugs:
    • Tub-040
    Belgium Germany Romania Spain

  • Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Crisantaspase
    • Inotuzumab Ozogamicin
    • Mitoxantrone Hydrochloride
    Austria Belgium Czechia Denmark Finland France +10

  • Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    Austria Belgium France Italy The Netherlands Norway +3

  • Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    • Topotecan
    Austria Belgium Czechia France Germany Greece +7

  • Study of Linvoseltamab in Adults with Relapsed or Refractory Multiple Myeloma

    Recruiting

    2 1 1
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Linvoseltamab
    • Dexamethasone
    Belgium Spain

  • Study on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Ixekizumab
    • Secukinumab
    • Guselkumab
    Belgium

  • Study on the Effects of Mexiletine for Treating Myotonic Dystrophy Types 1 and 2 in Patients

    Recruiting

    3 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • Mexiletine Hydrochloride
    Belgium Denmark Germany Italy Spain

  • Study of zongertinib tablets in patients with advanced solid tumors that have HER2 gene changes

    Recruiting

    2 1 1
    Investigated Drugs:
    • Zongertinib
    Belgium France Germany Italy The Netherlands Norway +1

  • Study of fluorouracil, irinotecan and oxaliplatin combination therapy for patients with metastatic pancreatic ductal adenocarcinoma who progressed after gemcitabine treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    Investigated Drugs:
    • Levoleucovorin
    • Levoleucovorin Disodium
    • Fluorouracil
    Belgium

  • Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Tebentafusp
    Belgium France Germany Ireland Italy The Netherlands +3
Previous Page
1 … 13 14 15 16 17 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!